Next Article in Journal
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Previous Article in Journal
Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia
Article

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

1
Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burg Oudlaan 50, 3062 PA Rotterdam, The Netherlands
2
IQVIA, Herikerbergweg 314, 1101 CT Amsterdam, The Netherlands
3
Department of Medical Oncology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2313; https://doi.org/10.3390/cancers12082313
Received: 30 June 2020 / Revised: 5 August 2020 / Accepted: 7 August 2020 / Published: 17 August 2020
(This article belongs to the Section Cancer Informatics and Big Data)
Background. Many new cancer medicines have been developed that can improve patients’ outcomes. However, access to these agents comes later in Europe than in the United States (US). The aim of this study is to assess the access in Europe to newly registered cancer drugs and to get more insight in the implications of these variations for patients. Methods. A retrospective database study was conducted. Analyses involved 12 cancer drugs and 28 European countries in the period 2011–2018. Time to patient access, speed of drug uptake, and the potential loss of life years due to a delay in access have been studied. Results. Marketing approval for the cancer drugs came on average 242 days later in Europe than in the US, and actual patient access varied extensively across Europe. The average time to market in Europe was 403 days (range 17–1187 days). The delay in patient access of ipilimumab and abiraterone may have led to a potential loss of more than 30,000 life years. Conclusion. It takes a long time for patients to get access to newly registered cancer drugs and there is great variation in access. The health outcomes can be substantially improved by faster processes. View Full-Text
Keywords: cancer drugs; access; delay; inequality; life years cancer drugs; access; delay; inequality; life years
Show Figures

Figure 1

MDPI and ACS Style

Uyl-de Groot, C.A.; Heine, R.; Krol, M.; Verweij, J. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. Cancers 2020, 12, 2313. https://doi.org/10.3390/cancers12082313

AMA Style

Uyl-de Groot CA, Heine R, Krol M, Verweij J. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. Cancers. 2020; 12(8):2313. https://doi.org/10.3390/cancers12082313

Chicago/Turabian Style

Uyl-de Groot, Carin A., Renaud Heine, Marieke Krol, and Jaap Verweij. 2020. "Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe" Cancers 12, no. 8: 2313. https://doi.org/10.3390/cancers12082313

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop